The findings can be used in patient counseling. Research confirms the clinical benefit of assessing bone biomarkers in hormone-sensitive prostate cancer.
R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma, which highlights the ongoing research that is being conducted at the University of California Davis Comprehensive Cancer Center.
Jonathan W. Riess, MD, MS, discusses how prior data led to the investigation of IO102-IO103 in combination with pembrolizumab in patients with PD-L1–high non–small cell lung cancer adenocarcinoma and details the initial efficacy and safety data reported in this population.
There may actually be a way to kill cancer cells with a “kill switch.” Researchers from the University of California Davis Comprehensive Cancer Center in Sacramento, California say they have discovered a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can simply make the cancer cells die. […]
For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free survival.